A novel t(Y;11) translocation with MLL gene rearrangement in a case of acute myelomonocytic leukemia (AML-M4)

TO THE EDITOR
In the May issue of Leukemia 10 novel 11q23 chromosomal partner sites, discovered by the European 11q23 Workshop participants, were reported. 1 Previously, more than 25 chromosome bands, belonging to autosomes and to the X chromosome, have been found rearranged with 11q23. Therefore, about 35 chromosome bands are involved in translocations with 11q23. The MLL gene, residing within that chromosome band, is often disrupted by the chromosome rearrangement, however, in many of these cases information about MLL status is unavailable. The short arm of the Y chromosome has never been found rearranged with 11q23. Here, we describe the first patient carrying a t(Y;11)(p11;q23) translocation and a complex karyotype (due to the presence of more than three cytogenetic abnormalities). He was a 41-year-old man who came to our attention in February 1995. He complained of fatigue and of bone pains. On admission to our ward physical examination showed a phlebothrombosis involving the right arm, cutaneous nodules localized on both feet and no hepatosplenomegaly. His full blood count was as follows: hemoglobin 11.0 g/dl, white blood cell (WBC) count 6.8 × 10 9 /l (differential: neutrophils 12%, lymphocytes 68% and blast cells 22%), platelets 19 × 10 9 /l. A bone marrow aspirate showed the almost exclusive presence (80%) of blast cells, that on cytochemistry were PAS negative, 30% Sudan black positive, 60% chloro-acetate esterase positive only partially inhibited. Leukemic cells displayed a high HLA-DR, CD33 and CD13 positivity. Cytogenetic analysis was performed on bone marrow cells from short-term unstimulated cultures with the QFQ-banding technique. Chromosomal abnormalities were described according to ISCN. 2 The karyotype was as follows: 47,XY,del(5)(q13q33),t(6;?)(p22;?),t(6;?)(p22;?),+6,+8,+9, +10,−15,t(16;18)(q12;q11),−21,−22/47,XY,t(2;5)(q21;p13),del (5)(q13q33),t(6;?)(p22;?),t(6;?)(p22;?),+6,+8,+9,+10,−15,t(16; 18)(q12;q11),−21,−22/47,X,t(Y;11)(p11;q23),del (5) Figure 1 ). Fluorescence in situ hybridization (FISH) on cytogenetic preparations was carried out on the same cell with a painting probe for chromosome 11, with a probe covering the heterochromatic region of the Y chromosome and with the MLL (11q23) DNA probe. This last one, specific for the MLL locus, detects the majority of rearrangements at this same locus by showing a large signal on the normal chromosome 11 and two smaller spots, one on the abnormal number 11 and one at the site of the translocation. The MLL probe does not discover rearrangements involving the 3Ј end of the gene. All probes were commercially obtained (Oncor, Gaithersburg, MD, USA). The first two were biotin-labeled (green signals), the MLL probe was digoxigenin-labeled (red signal). Hybridization was performed according to the manufacturer's guidelines. First we applied the chromosome 11 painting probe. We observed three small green signals: one corresponding to the normal number 11, the second due to the rearranged number 11 and the third localized on the short arm of the Y chromosome, recognizable for its brillant heterochromatic region. In the successive step we identified the Y chromosome better as we utilized the probe specific for its heterochromatic region (Figure 2a-c) . Lastly, the MLL probe showed a red signal on the normal number 11. The other signal had been split by the Y;11 translocation as two smaller spots, one on the rearranged 11 and the other on the Y chromosome (Figure 2a 1 -c 1 ) .
A diagnosis of acute myelo-monocytic leukemia (AML-M4) was made. A chemotherapy regimen consisting of idarubicine 15 mg/m 2 on the first day, cytosine-arabinoside (Ara-C) 125 mg/m 2 every 12 h for 5 days and etoposide 60 mg/m 2 every 12 h for 5 days was started. The patient did not respond to this treatment schedule and therefore Ara-C 3 g/m 2 every 12 h for 3 days was started. The patient died of sepsis during the period of pancytopenia.
Our present report is the first one indicating that even the short arm of the Y chromosome may be a partner site for band 11q23 translocations. At first, considering cytogenetic data only, we defined the chromosome 11 abnormality as del(11)(q23). However, the clinico-hematological features of our patient (young age, M4-M5 cytotype, high HLA-DR expression) were those typically associated with balanced abnormalities of number 11. 3 FISH confirmed that such a case
Figure 1
Partial QFQ-banded karyotype, showing the normal chromosome 11, the der(11) and the der(y). At the bottom is the schematic diagram of the translocation.
had in fact occurred in our patient too. The technique identified the t(Y;11) and showed that the MLL gene had been disrupted by the rearrangement, being split between chromosomes Y and 11. This datum further underlines the clear-cut difference existing between balanced and unbalanced (deletions) abnormalities of chromosome 11, as, in the latter, the MLL gene tends not to be involved. 4 Cytogenetic and molecular analyses have convincingly demonstrated that it is the der(11) that harbors the leukemogenic transcript, ie expression of the 5Ј MLL-3Ј partner chimeric protein is the important outcome. 5 This event has surely occurred in our patient also. On the other hand, the partner chromosome seems to have only a minor role. The 5Ј partner-3Ј MLL fusion messengers are inconsistently detected by transcription studies. In some cases, however, the nature of the partner gene or the fact that it must rearrange at a certain stage of hemopoietic differentiation makes its involvement more specifically associated with a peculiar subtype of malignant proliferation. Recently, the trivial role of the partner gene has been further underlined by the fact that in ANLL patients with a normal karyotype, the MLL gene may undergo tandem duplication with self-fusion points distributed within the breakpoint cluster region of the gene in a manner similar to its translocation breakpoints. 6 It has been shown that Alu sequences are present at a high density within the MLL breakpoint cluster region and they may make that region more prone to recombination events. As far as the Y chromosome is concerned, in myeloid malignancies most of its structural abnormalities involve the heterochromatic region. In the present case, however, the breakpoint on the Y chromosome has been tentatively assigned to band Yp11.3. To the best of our knowledge, that band does not contain any gene important for hemopoietic differentiation or for malignant transformation. However, we must remember that Yp11.3 is one of the pseudoautosomal regions of the Y chromosome, the other being localized at the end of Yq. Yp11.3 is identical to the corresponding Xp region, with which it recombines during meiosis. It contains sequences that exhibit a high frequency of base substitutional polymorphisms, together with almost complete linkage disequilibrium, in order to create only few diverged haplotypes. Moreover, its boundary is densely populated with Alu repeats. 7 Therefore, we suggest that in our patient the Y chromosome has been involved in the t(Y;11) only because of its high content in Alu repeats and in sequences with a high recombination rate.
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